Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

CollPlant Biotechnologies Ltd. (CLGN)

12.99   1.78 (15.88%) 01-27 15:59
Open: 11.21 Pre. Close: 11.21
High: 13.02 Low: 10.97
Volume: 58,569 Market Cap: 145(M)

Technical analysis

as of: 2023-01-27 4:43:24 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 15.2     One year: 17.76
Support: Support1: 9.71    Support2: 7.67
Resistance: Resistance1: 13.02    Resistance2: 15.2
Pivot: 9.44
Moving Average: MA(5): 10.81     MA(20): 9.25
MA(100): 7.43     MA(250): 8.56
MACD: MACD(12,26): 0.8     Signal(9): 0.5
Stochastic oscillator: %K(14,3): 90.5     %D(3): 83.6
RSI: RSI(14): 78.6
52-week: High: 14.77  Low: 4.26
Average Vol(K): 3-Month: 32 (K)  10-Days: 24 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CLGN ] has closed It is unclear right now based on current values. 137.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 13.04 - 13.1 13.1 - 13.16
Low: 10.84 - 10.9 10.9 - 10.96
Close: 12.87 - 12.99 12.99 - 13.1

Company Description

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

Headline News

Sat, 28 Jan 2023
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest ... - MarketBeat

Fri, 27 Jan 2023
Top 5 Health Care Stocks That May Dip - Benzinga

Tue, 24 Jan 2023
CollPlant Issues Letter to Shareholders - January 24, 2023 - BioSpace

Tue, 17 Jan 2023
Should You Sell Collplant Biotechnologies Ltd - ADR (CLGN) in Biotechnology Industry? - InvestorsObserver

Thu, 05 Jan 2023
CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) market cap rose US$13m last week; individual investors who hold 50% profited and so did insiders - Simply Wall St

Wed, 04 Jan 2023
Collplant Biotechnologies Ltd - ADR (CLGN) is higher by 10.25% in a Week, Should You Sell? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 11 (M)
% Held by Insiders 7.75e+006 (%)
% Held by Institutions 10.1 (%)
Shares Short 27 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.481e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 870.2
Return on Equity (ttm) -21
Qtrly Rev. Growth 551000
Gross Profit (p.s.) -32.03
Sales Per Share -56.05
EBITDA (p.s.) 1.97681e+007
Qtrly Earnings Growth -1.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -13 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.24
Price to Cash Flow 2.77

Stock Dividends

Dividend 0
Forward Dividend 24610
Dividend Yield 0%
Dividend Pay Date 2016-11-20
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.